Literature DB >> 31235086

Comparison of primary versus secondary prevention of cardiovascular disease in patients with type2 diabetes: Focus on achievement of ABC goals.

Soghra Rabizadeh1, Mohammad Ali Mansournia2, Salome Sadat Salehi3, Pegah Khaloo4, Hamid Alemi5, Hassan Mirbolouk6, Micheal Joseph Blaha7, Alireza Esteghamati8, Manouchehr Nakhjavani9.   

Abstract

BACKGROUND: Primary and secondary prevention of cardiovascular disease is of utmost importance in the management of patients with diabetes.
OBJECTIVES: We studied a group of Iranian patients with type2 diabetes to provide an overview of the current status of secondary prevention of cardiovascular disease in the Middle East.
METHODS: This is a cross-sectional study of 2029 Patients with type2 diabetes including 323 patients with coronary artery disease (CAD) were recruited. Achievement of goals in HbA1c (A), blood pressure (B) and LDL-cholesterol(C) was assessed.
RESULTS: The study showed 25.3% of CAD positive patients achieved HbA1c <7% compared to 30% in CAD negative patients. The achievement of blood pressure ≤140/90 mmHg was 53.2% and 52.8% in CAD positive and CAD negative patients respectively. There was no difference in the achievement of all three ABC goals between the two groups (p = 0.733). After logistic regression analysis, history of hypertension had the highest odds ratio for CAD.
CONCLUSION: Although ABC control has an important impact on the prevention of cardiovascular outcomes, the ideal goal needs further efforts to be achieved.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Cardiovascular risk factors; Coronary artery disease; Primary prevention; Secondary prevention; Type 2 diabetes

Year:  2019        PMID: 31235086     DOI: 10.1016/j.dsx.2019.03.043

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  1 in total

1.  Prevalence, Awareness, Treatment, Control, and the Associated Factors of Diabetes in an Iranian Kurdish Population.

Authors:  Roya Safari-Faramani; Fatemeh Rajati; Kamran Tavakol; Behrooz Hamzeh; Yahya Pasdar; Mehdi Moradinazar; Farid Najafi
Journal:  J Diabetes Res       Date:  2019-09-03       Impact factor: 4.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.